SARS-CoV-2 and RSV external quality assessment on molecular detection and variant typing in European expert laboratories in 2025
6 affiliations
- 1Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humbolt-Universität zu Berlin, Berlin, Germany
- 2Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
- 3Molecular Mechanisms of Multiplication of Pneumoviruses Unit (M3P), Institut Pasteur, Université Paris-Saclay, Université de Versailles St. Quentin, Université Paris Cité, UMR 1173 (2I), INSERM, Centre National de Reference Virus des Infections Respiratoires (CNR VIR), Assistance Publique des Hôpitaux de Paris, Paris, France
- 4European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- 5German Centre for Infection Research (DZIF), associated partner site Charité, Berlin, Germany
- 6Labor Berlin-Charité Vivantes, Berlin, Germany
Abstract
We herein report on the fourth SARS-CoV-2 wet-lab external quality assessment (EQA) and the second organized by the AURORAE consortium to assess the diagnostic capabilities of European expert public health laboratories. Diagnostic capabilities were investigated regarding SARS-CoV-2 and, for the first time, respiratory syncytial virus (RSV) groups A and B. A 10-sample panel containing various SARS-CoV-2 variants, RSV lineages, a common cold coronavirus, and a negative control was produced and validated. Participants were invited by the European Centre for Disease Prevention and Control (ECDC) and asked to submit results and assay details via electronic forms. Thirty-seven laboratories from 32 European countries participated. All panel samples were identified correctly via molecular detection by 23 participating laboratories (23/37; 62%). Commercial assays were used most often (23/37; 62%), in comparison to in-house assays (14/37; 38%), or a combination of both (8/37; 22%). RSV groups were correctly determined by 20 laboratories (20/37; 54%). The optional task of SARS-CoV-2 variant typing was performed by 20 laboratories using next-generation sequencing. Thirteen laboratories successfully generated SARS-CoV-2 sequences. Six laboratories performed optional RSV sequencing, with only two obtaining sequences. The current and previous EQAs show that molecular detection of SARS-CoV-2 within Europe has improved over time and is now at a consistently high level. Molecular detection of RSV samples with low viral load was challenging, as was lineage identification for low-concentration specimens. Routine monitoring of diagnostic and surveillance assays via EQAs remains key to maintaining rapid and long-lasting public health laboratory response systems. IMPORTANCE External quality assessments (EQAs) are essential for ensuring reliable and consistent diagnostic testing. They provide an objective way to evaluate laboratory performance, identify weaknesses, and drive improvements, as well as ensuring compliance with accreditation standards. Furthermore, participating in EQAs strengthens the contributions to public health disease surveillance and threat detection on national and transborder scales. During the SARS-CoV-2 pandemic, EQAs were vital for maintaining accuracy in the setting of increasing testing demands and emerging variants. Broadening of diagnostic testing to a wider panel of viruses, including respiratory syncytial virus (RSV), requires continuous performance monitoring to ensure accuracy and reliability. Ongoing development of vaccines and therapeutics, which may drive the emergence of new mutations, further underscores the need for regular evaluation of test effectiveness. By standardizing methods and reducing errors, EQAs ensure trustworthy and comparable results across laboratories. Regular participation in EQAs strengthens molecular diagnostics and variant surveillance.
Related
- Interlaboratory comparison of molecular detection of Cyclospora cayetanensis in routine diagnostic laboratories
- PlasmiDB: an open-source and customizable database for plasmid lifecycle management in multi-user, multi-project plant molecular biology laboratories
- First Detection of Hemotropic Mycoplasma sp. in Cetaceans of European Waters.
- Introgression among maternal lineages inferred from complete mitogenomes and molecular dating helps resolve phylogeography of European roe deer
- Multiplex species-specific real-time PCR assays for the detection of European Armillaria spp. and Desarmillaria spp. in different environmental substrates
BibTeX
@article{heimsch2026sarscov2,
title = {{SARS-CoV-2 and RSV external quality assessment on molecular detection and variant typing in European expert laboratories in 2025}},
author = {Kim C. Heimsch and Kamelia R. Stanoeva and Ingmar Visser and Yannis Rahou and Tobias Bleicker and Alawiya Reslan and Danielle Perez-Bercoff and Eeva K. Broberg and Chantal B. E. M. Reusken and Victor M. Corman and Christian Drosten and Adam Meijer and Marie-Anne Rameix-Welti},
journal = {Journal of Clinical Microbiology},
year = {2026},
month = sep,
doi = {10.1128/jcm.00258-26},
url = {https://pasteur.hal.science/pasteur-05760250v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - SARS-CoV-2 and RSV external quality assessment on molecular detection and variant typing in European expert laboratories in 2025
AU - Kim C. Heimsch
AU - Kamelia R. Stanoeva
AU - Ingmar Visser
AU - Yannis Rahou
AU - Tobias Bleicker
AU - Alawiya Reslan
AU - Danielle Perez-Bercoff
AU - Eeva K. Broberg
AU - Chantal B. E. M. Reusken
AU - Victor M. Corman
AU - Christian Drosten
AU - Adam Meijer
AU - Marie-Anne Rameix-Welti
PY - 2026
DA - 2026/09/17
JO - Journal of Clinical Microbiology
DO - 10.1128/jcm.00258-26
UR - https://pasteur.hal.science/pasteur-05760250v1
AB - We herein report on the fourth SARS-CoV-2 wet-lab external quality assessment (EQA) and the second organized by the AURORAE consortium to assess the diagnostic capabilities of European expert public health laboratories. Diagnostic capabilities were investigated regarding SARS-CoV-2 and, for the first time, respiratory syncytial virus (RSV) groups A and B. A 10-sample panel containing various SARS-CoV-2 variants, RSV lineages, a common cold coronavirus, and a negative control was produced and validated. Participants were invited by the European Centre for Disease Prevention and Control (ECDC) and asked to submit results and assay details via electronic forms. Thirty-seven laboratories from 32 European countries participated. All panel samples were identified correctly via molecular detection by 23 participating laboratories (23/37; 62%). Commercial assays were used most often (23/37; 62%), in comparison to in-house assays (14/37; 38%), or a combination of both (8/37; 22%). RSV groups were correctly determined by 20 laboratories (20/37; 54%). The optional task of SARS-CoV-2 variant typing was performed by 20 laboratories using next-generation sequencing. Thirteen laboratories successfully generated SARS-CoV-2 sequences. Six laboratories performed optional RSV sequencing, with only two obtaining sequences. The current and previous EQAs show that molecular detection of SARS-CoV-2 within Europe has improved over time and is now at a consistently high level. Molecular detection of RSV samples with low viral load was challenging, as was lineage identification for low-concentration specimens. Routine monitoring of diagnostic and surveillance assays via EQAs remains key to maintaining rapid and long-lasting public health laboratory response systems. IMPORTANCE External quality assessments (EQAs) are essential for ensuring reliable and consistent diagnostic testing. They provide an objective way to evaluate laboratory performance, identify weaknesses, and drive improvements, as well as ensuring compliance with accreditation standards. Furthermore, participating in EQAs strengthens the contributions to public health disease surveillance and threat detection on national and transborder scales. During the SARS-CoV-2 pandemic, EQAs were vital for maintaining accuracy in the setting of increasing testing demands and emerging variants. Broadening of diagnostic testing to a wider panel of viruses, including respiratory syncytial virus (RSV), requires continuous performance monitoring to ensure accuracy and reliability. Ongoing development of vaccines and therapeutics, which may drive the emergence of new mutations, further underscores the need for regular evaluation of test effectiveness. By standardizing methods and reducing errors, EQAs ensure trustworthy and comparable results across laboratories. Regular participation in EQAs strengthens molecular diagnostics and variant surveillance.
SN - 0095-1137
SN - 1098-660X
ER -